-
-
After late-study endpoint switch, Aldeyra hails success of phase 3 dry eye disease trial
-
DBV patches up prospects with phase 3 win in infants with peanut allergies
Systems biology, machine learning can boost trial success rates, says MIM
Black breast cancer patients want to participate in trials, but adequate information is hard to come by
Weight watcher: Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data
In The News
- Economic Storm Clouds Hovering Over Trump and Global Leaders August 25, 2019 By News Team
- UN: Possible to Eradicate Malaria, but Probably Not Soon August 24, 2019 By News Team
- Climate Change Turns Arctic Into Strategic, Economic Hotspot August 23, 2019 By News Team
Biotechnology Daily
more-
After late-study endpoint switch, Aldeyra hails success of phase 3 dry eye disease trial
Aldeyra Therapeutics’ late-study primary endpoint switch has paid off. Weeks after disclosing the change to…
DBV patches up prospects with phase 3 win in infants with peanut allergies
Systems biology, machine learning can boost trial success rates, says MIM
Black breast cancer patients want to participate in trials, but adequate information is hard to come by
Apple Watch’s ‘AFib History’ feature ripens with new FDA clearance
Market Watch
more-
Weekly Market Review – July 2, 2022
Stock Markets Over the week just concluded, the stock markets showed took a further dip…
Oil prices eye first gain in 3 sessions as supply worries resurface
Kohl’s failed takeover was just one of a wave of abandoned deals amid market volatility
Why it seems that all of your trusty stock-market indicators are busted
Stocks could drop 50%, Nouriel Roubini argues. Things will get much worse before they get better.
Bio Business News
moreWeight watcher: Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data
Innovent is catching up with the likes of Eli Lilly…
Mineralys hauls in $118M series B to advance hypertension med through phase 2 trial
Mineralys Therapeutics has raked in $118 million in series B…
Ginkgo Bioworks picks up Bitome’s AI to bolster its cell engineering platform
Reprogramming cells to create specific molecules is no walk in…
World News
moreStocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Weekly Market Review – July 2, 2022
After late-study endpoint switch, Aldeyra hails success of phase 3 dry eye disease trial
DBV patches up prospects with phase 3 win in infants with peanut allergies
Systems biology, machine learning can boost trial success rates, says MIM
Black breast cancer patients want to participate in trials, but adequate information is hard to come by
Weight watcher: Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data
Mineralys hauls in $118M series B to advance hypertension med through phase 2 trial
Ginkgo Bioworks picks up Bitome’s AI to bolster its cell engineering platform
Embecta’s CEO on juggling a double life as a BD spinout and new diabetes tech player
Oil prices eye first gain in 3 sessions as supply worries resurface